Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma

Authors

Melissa M Yamada, Washington University School of Medicine in St. Louis
Smitha Chandrasekhar, University of Washington
Ted A Gooley, Fred Hutchinson Cancer Center
Rita E Chen, Washington University School of Medicine in St. Louis
Coley Doolittle-Amieva, University of Washington
George Ansstas, Washington University School of Medicine in St. Louis
Shailender Bhatia, University of Washington
Evan T Hall, University of Washington
Paul T Nghiem, University of Washington
Song Y Park, University of Washington
David Y Chen, Washington University School of Medicine in St. Louis

Journal

Journal for Immunotherapy of Cancer

Publication Date

12-25-2025

Volume

13

Issue

12

First Page

e013564

Document Type

Open Access Publication

DOI

10.1136/jitc-2025-013564

Rights and Permissions

Yamada MM, Chandrasekhar S, Gooley TA, Chen RE, Doolittle-Amieva C, Ansstas G, Bhatia S, Hall ET, Nghiem PT, Park SY, Chen DY. Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma. J Immunother Cancer. 2025 Dec 25;13(12):e013564. doi: 10.1136/jitc-2025-013564. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license

Recommended Citation

Yamada, Melissa M; Chandrasekhar, Smitha; Gooley, Ted A; Chen, Rita E; Doolittle-Amieva, Coley; Ansstas, George; Bhatia, Shailender; Hall, Evan T; Nghiem, Paul T; Park, Song Y; and Chen, David Y, "Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma." Journal for Immunotherapy of Cancer. 13, 12. e013564 (2025).
https://digitalcommons.wustl.edu/oa_4/6062

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.